# **ORIGINAL ARTICLE**

# OESOPHAGEAL VARICES AND ASSOCIATED FACTORS IN CIRRHOTIC PATIENTS WITH HEPATITIS C

# Saira Muhammad Ali, Syed Zea ul Islam Farrukh, Syed Afzal ul Haq Haqqi, Arif Rasheed Siddiqui, Muhammad Zahid Qadri, Saad Khalid Niaz

Patel Hospital Karachi, Civil Hospital Karachi-Pakistan

Background: Infection with hepatitis C virus is reported to have infected almost 71 million people worldwide. This study was done to assess the frequency and associated factors leading to oesophageal varices in patients presenting with hepatitis C related liver cirrhosis. Methods: A cross-sectional study was conducted at Patel Hospital, Karachi, Pakistan from 9th May to 5th October 2019. Patients of either gender having age >20 years presenting with HCV related liver cirrhosis, and Child Pugh class A, B and C were consecutively enrolled in the study. Data on variables like: age, gender, Childs Pugh Score (A/B/C), smoking status, laboratory characteristics like hemoglobulin (Hb), TLC, platelets, serum albumin level, cholesterol, alkaline phosphate (ALK), alkaline transaminase (ALT), ascites and presence of oesophageal varices was recorded and analysed using SPSS-21.0. Results: Out of 167 patients, mean age was 44.86±14.74 years. Eight-nine (53.3%) of the patients were males. The mean duration of cirrhosis was 5.78±1.10 months. Thrombocytopenia was observed in majority (n=130, 77.8%) of the patients. There were 33 (19.8%) patients with Child Pugh score A while Child-Pugh score B and C was found in 67 (40.1%) each. The frequency of oesophageal varices was 141 (84.4%). A significantly higher proportion of oesophageal varices were found among thrombocytopenic patients (p<0.001), ascites (p-0.024), and having "C" Child-Pugh score (p-0.012). Conclusion: Oesophageal varices were found in a considerable proportion. Thrombocytopenia, ascites and Child-Pugh class C were found as leading contributing factors to oesophageal varices.

**Keywords** Oesophageal varices; Thrombocytopenia; Child-Pugh score; Hepatitis C; Liver cirrhosis

Citation: Ali SM, Farrukh SZI, Haqqi SAH, Siddiqui AR, Qadri MZ, Niaz SK. Oesophageal varices and associated factors in cirrhotic patients with Hepatitis C. J Ayub Med Coll Abbottabad 2022;34(4):834–7.

**DOI:** 10.55519/JAMC-04-10746

#### INTRODUCTION

Infection with hepatitis C virus is reported as one of the leading causes of morbidity and mortality related to health with ever-increasing frequency. Almost 71 million people have been infected with chronic hepatitis C worldwide. Prevalence of HCV infection in Pakistan is 4.8%. Patients who are infected acutely due to HCV infection, 50-70% of them will develop chronic liver disease. Chronic infection can lead to cirrhosis, liver cancer and liver failure.<sup>1,2</sup> This requires a large proportion of health-related services because of its feared complications resulting in prolonged hospitalization and need for liver transplantation.<sup>3</sup> Cirrhosis is histologically defined as liver parenchyma fibrosis and the conversion into abnormal nodules of normal liver architecture.4 Cirrhosis is among the leading causes of death and results serious complications like ascites, encephalopathy, spontaneous bacterial peritonitis and variceal hemorrhage.<sup>5,6</sup> Oesophageal varices are known to be dilated submucosal veins that occur in patients with hypertension of the underlying portal.<sup>7,8</sup>

We planned this study to find out the frequency and factors leading to oesophageal varices in patients

presenting with hepatitis C virus related liver cirrhosis in order to establish the local perspective as there is paucity of local data on screening study for oesophageal varices. As the outcomes are poor, prevention and regular screening are the only tools in preventing fatal complications once variceal bleeding has occurred. Data from this study would help in understanding the disease burden and its determinants in our population and timely detection and management of varices may lead to good quality of life.

#### MATERIAL AND METHODS

A cross-sectional study was carried out at the Patel Hospital in Karachi Pakistan from 9th May to 5th October 2019. Ethical considerations were addressed prior to conducting the study. The study's intent and protocol were clarified to the patient included in this study after obtaining informed consent.

Patients of either gender having age >20 years presenting with hepatitis C related liver cirrhosis, with Child Pugh class A, B and C were consecutively included. Whereas patients with history of prior diagnostic evaluations who underwent endoscopy, known to have oesophageal varices, not fit for endoscopy with

history of congestive cardiac failure, stroke, asthma, COPD, chronic renal failure or myocardial infarction, history of NSAID use or non-consenting patients were excluded. The required sample size of 167 was calculated using World Health Organization software with assumptions of reported prevalence of oesophageal varices as 69.3%, onfidence level of 95%, and absolute precision of 7%.

Upper GI endoscopy was done with the help of Olympus video gastroscope by an gastroenterologist who had experience of procedure for more than 5 years. Local anaesthetic, 4% xylocaine solution was used for gargles before the procedure and injection midazolam intravenous was given if required. Hepatitis C virus related liver cirrhosis was defined as hepatitis C antibody positive (ELISA method) for more than one year presenting with any 3 or more of the following on ultrasound including: reduction of liver size, nodularity of liver surface (labelled as positive when liver surface showed irregularity and humping), coarsening of liver echotexture (labelled as positive when decreased echogenicity) when assessed by ultrasound abdomen, ascites, and portal hypertension.

Oesophageal varices are abnormal enlarged vessels proven by endoscopy. Presence of one or more column of dilated veins in the oesophagus was labelled as oesophageal varices. In order to assess the prognoses of chronic liver diseases, classification was done as Child-Pugh scores A, B and C, based on severity of the liver disease. Whereas a person who smokes at least five cigarettes a day for at least one year was labelled a smoker.

The findings of quantitative and categorical variables (age, gender, Childs Pugh Score (A/B/C), smoking status, laboratory characteristics like hemoglobulin (Hb), TLC, platelets, serum albumin level, cholesterol, alkaline phosphate (ALK), alkaline transaminase (ALT), ascites and presence of oesophageal varices were noted.

Data analysis was done using SPSS 21.0. Mean and standard deviation was used to describe for age, duration of cirrhosis, Hb, TLC, platelets, serum albumin level, cholesterol, ALK, and ALT. Frequency and percentages were used to describe gender, smoking status, thrombocytopenia, ascites, Child Pugh score, and oesophageal varices. Chi-square test and independent t-test were used to apply inferential statistics. *p*-value equal to 0.05 has been taken as significant.

#### RESULTS

Of 167 patients, mean age was  $44.86 \pm 14.74$  years. There were 89 (53.3%) males and 78 (46.7%) females. The mean duration of cirrhosis was  $5.78 \pm 1.10$  months. There were 55 (32.9%) smokers.

The mean haemoglobin, TLC, and platelet was found to be 7.06±0.76 g/dl, 7.76±6.17 x 1000/ $\mu$ L, and

 $95.39 \pm 91.13 \text{ x } 1000/\mu\text{L}$  respectively. Thrombocytopenia was observed in majority (n=130, 77.8%) of the patients. There were 33 (19.8%) patients with child pugh score A while B and C child pugh score were observed in 67 (40.1%) each.

The majority of the patients (n=141, 84.4%) had oesophageal varices. A statistically significant association of oesophageal varices was found among patients who were thrombocytopenic (p-0.001), having ascites (p 0.024), and having Child-Pugh score "C" (p 0.012). In particular, out of 141 patients with oesophageal varices, thrombocytopenia was found in 123 (87.23%) patients while 18 (12.76%) patients had no thrombocytopenia. Ascites was found in 126 (89.36%) patients with oesophageal varices whereas 15 (10.63%) patients with oesophageal varices had no oesophageal varices. In addition, a significantly higher proportion (n=62, 93%) of the child pugh score "C" was reported among patients with oesophageal varicose veins, followed by the "B" in 56 (84 percent), while "A" was reported among 23 (70 percent) of the patients.




Figure 1: Frequency of oesophageal varices (n=167)

Table 1: Comparison of oesophageal varices with

predicting variables (n=167)				
Variables	Total	Oesophageal Varices		
		Yes	No	<i>p</i> -value
		(n=141)	(n=26)	_
	n	n (%)	n (%)	
Gender				
Male	89	73 (82)	16 (18)	0.359
Female	78	68 (87)	10 (13)	
Smoking status				
Smokers	55	47 (85)	8 (15)	0.798
Non-smokers	112	94 (84)	18 (16)	
Thrombocytopenia	ì			
Yes	130	123 (95)	7 (5)	0.001
No	37	18 (49)	19 (51)	
Ascites				
Yes	145	126 (87)	19 (13)	0.024
No	22	15 (68)	7 (32)	
Child Pugh Score				
A	33	23 (70)	10 (30)	0.012
В	67	56 (84)	11 (16)	
C	67	62 (93)	5 (8)	
All data presented a	s numbe	r (%),		
Chi-square test applied n-value < 0.05 taken as significant				

Chi-square test applied, *p*-value <0.05 taken as significant

Variables Oesophageal Varices Yes (n=141) No (n=26) Overall *p*-value Age, years  $44.86 \pm 14.74$ 45.37 ±14.07 42.08 ±17.99 0.297 Duration of cirrhosis, months 5.78 ±1.10 5.81 ±1.12  $5.69 \pm 0.97$ 0.645 Haemoglobin, g/dl  $7.06 \pm 0.78$  $7.02 \pm 0.65$  $7.06 \pm 0.76$ 0.811 TLC, x 1000/μL 7.76 ±6.17  $7.54 \pm 6.06$  $8.98 \pm 6.72$ 0.275 Platelet, x 1000/μL 95.39 ±91.13 79.68 ±71.02 180.57 ±134.01 < 0.001  $19.19 \pm 15.41$  $14.01 \pm 6.13$ Alpha fetoprotein  $20.30 \pm 16.55$ 0.106  $\overline{126.25 \pm 17.67}$ 126.34 ±17.34 125.77 ±19.78 Cholesterol 0.88 33.92 ±6.56 0.159 HDL  $35.47 \pm 6.12$  $35.76 \pm 6.02$ 65.77 ±9.76 0.049 LDL  $69.68 \pm 11.05$  $70.41 \pm 11.15$ 120.95 ±23.89  $1\overline{25.51} \pm 22.92$ 0.293 TGL  $120.12 \pm 24.05$ Bilirubin, mg/dL 1.59 ±0.91 1.69 ±0.97 1.56 ±0.90 0.523 Alkaline Phosphate, IU/L 1.47 ±0.62  $1.50 \pm 0.64$  $1.31 \pm 0.47$ 0.139 Alkaline Transaminase, IU/L 2.81 ±0.59 2.81 ±0.58  $2.78 \pm 0.63$ 0.867 All data presented as median (IQR), p-value <0.05 was taken as significant

Table 2: Median difference of clinical and laboratory characteristics with the presence of oesophageal varices (n=167)

#### DISCUSSION

In all cirrhotic cases, oesophageal varicose veins eventually develop and, when formed, tend to increase for size and bleed. Higher morbidity and mortality are associated with variceal haemorrhage than other forms of upper gastrointestinal bleeding At the time of diagnosis of liver cirrhosis, endoscopic screening is considered safe in all patients for oesophageal varicose veins. 10

The finding of this study showed oesophageal varices in 84.4% of the patients. A considerable number of patients with oesophageal varices had thrombocytopenia, ascites, and Child-Pugh score C. In particular, out of 141 patient oesophageal varices, thrombocytopenia was found considerably higher. Similarly, ascites was also found higher in patients with oesophageal varices. These findings matched with the published studies as well.11-17 Various previous studies reported the number of platelets per spleen diameter ratio as the viable non-invasive tool most for determination. 18-22

In our study, child pugh score "C" and "B" were considerably higher in patients with oesophageal varicose veins. Variceal bleeding is confirmed to be a life-threatening occurrence with a five-percent incidence in patients with small oesophageal varicose veins and up to fifteen percent in patients with large oesophageal varicose veins.<sup>23</sup> Different studies have reported a mortality rate of about 10–20% per bleeding episode, and a one-year survival rate of only sixty-three percent.<sup>24,25</sup>

Amin *et al* evaluated oesophageal varices prevalence in F4 stage of hepatitis C virus related hepatic-cirrhosis and found the prevalence to be 69.3% in Pakistan.<sup>9</sup>

Serum albumin concentration, portal vein diameter, and splenomegaly have been identified as independent variables for evaluating oesophageal varices in another study. <sup>16</sup> Though, small sample size will remain the limitation of this study. Despite of this, the current study has reported current magnitude of the problem in at risk population. As the incidence of hepatitis C and liver cirrhosis is remarkably increasing in Pakistan, identification of the predicting factors is vitally important for the management of the disease. Further multicentre large-scale studies are recommended to further validate the findings.

## **CONCLUSION**

A considerably higher proportion of oesophageal varices was observed in our cohort. Furthermore, thrombocytopenia, ascites and higher child pugh score were found significant leading factors.

### **AUTHORS' CONTRIBUTION**

SMA, SZUIF: Conceptualization of the study design, write-up. SAHH, ARS, MZQ, SKN: Data collection, data analysis, data interpretation, proof reading.

#### REFERENCES

- Gower E, Estes C, Blach S, Shearer KR, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014;61(1):S45–57.
- Mohamed AA, Elbedewy TA, El-Serafy M, El-Toukhy N, Ahmed W, Din El Din Z. Hepatitis C virus: a global view. World J Hepatol 2015;7(26):2676–80.
- 3. Raja NS, Janjua KA. Epidemiology of hepatitis C virus infection in Pakistan. J Microbiol Immunol Infect 2008;41(1):4–8.
- Foster GR, Irving WL, Cheung MC, Walker AJ, Hudson BE, Verma S, *et al*. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016;64(6):1224–31.
- Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet 2014;383:1749–61.
- Vizzutti F, Arena U, Romanelli RG, Rega L, Foschi M, Colagrande S, et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology 2007;45(5):1290–7.
- Merkel C, Zoli M, Siringo S. Prognostic indicators of risk for first variceal bleeding in cirrhosis: a multicenter study in 711 patients to validate and improve the North Italian Endoscopic

- Club (NIEC) index. Am J Gastroenetrol 2000;95(10):2915-20
- Jensen DM. Endoscopic screening for varices in cirrhosis: Findings, implications, and outcomes. Gastroenterology 2002;122(6):1620–30.
- Amin M, Jabbar MA, Ahmad H, Samar S. Association between presence of oesophageal varices on endoscopy and extreme degree of f4-stage fibrosis on fibroscan in hcvrelated chronic liver disease. Ulutas Med J 2018;4(2):85–9.
- Merli M, Nicolini G, Angeloni S, Rinaldi V, De Santis A, Merkel C, et al. Incidence and natural history of small oesophageal varices in cirrhotic patients. J Hepatol 2003;38(3):266–72.
- Zein CO, Lindor KD, Angulo P. Prevalence and predictors of oesophageal varices in patients with primary sclerosing cholangitis. Hepatology 2004;39(1):204–10.
- 12. Zaman A, Becker T, Lapidus J, Benner K. Risk factors for the presence of varices in cirrhotic patients without a history of variceal hemorrhage. Arch Intern Med 2001;161(21):2564–70.
- 13. Riggio O, Angeloni S, Nicolini G, Merli M, Merkel C. Endoscopic screening for oesophageal varices in cirrhotic patients. Hepatology 2002;35(2):501–2.
- Bressler B, Pinto R, El-Ashry D, Heathcote EJ. Which
  patients with primary biliary cirrhosis or primary sclerosing
  cholangitis should undergo endoscopic screening for
  ooesophageal varices detection? Gut 2005;54(3):407–10.
- Sanyal AJ, Fontana RJ, Di Bisceglie AM, Everhart JE, Doherty MC, Everson GT, et al. The prevalence and risk factors associated with oesophageal varices in subjects with hepatitis C and advanced fibrosis. Gastrointest Endosc 2006;64(6):855–64.
- Schwarzenberger E, Meyer T, Golla V, Sahdala NP, Min AD. Utilization of platelet count spleen diameter ratio in predicting the presence of oesophageal varices in patients with cirrhosis. J Clin Gastroenterol 2010;44(2):146–50.
- Thomopoulos KC, Labropoulou-Karatza C, Mimidis KP, Katsakoulis EC, Iconomou G, Nikolopoulou VN. Noninvasive predictors of the presence of large ooesophageal

- varices in patients with cirrhosis. Dig Liver Dis 2003;35(7):473–8.
- González-Ojeda A, Cervantes-Guevara G, Chávez-Sánchez M, Dávalos-Cobián C, Ornelas-Cázares S, Macías-Amezcua MD, et al. Platelet count/spleen diameter ratio to predict oesophageal varices in Mexican patients with hepatic cirrhosis. World J Gastroenterol 2014;20(8):2079–84.
- Ying L, Lin X, Xie ZL, Hu YP, Shi KQ. Performance of platelet count/spleen diameter ratio for diagnosis of oesophageal varices in cirrhosis: a meta-analysis. Dig Dis Sci 2012;57(6):1672–81.
- Amin K, Muhammad D, Anjum A, Jamil K, Hassan A. Platelet count to spleen diameter ratio as a predictor of oesophageal varices in patients of liver cirrhosis due to hepatitis C virus. J Univ Med Dent Coll 2012;3(1):6–11.
- Sezer OB, Celik D, Tutar N, Özçay F. Can platelet count/spleen diameter ratio be used for cirrhotic children to predict oesophageal varices? World J Hepatol 2016;8(33):1466–70.
- Jamil Z, Malik M, Durrani AA. Platelet count to splenic diameter ratio and other noninvasive markers as predictors of oesophageal varices in patients with liver cirrhosis. Turk J Gastroenterol 2017;28(5):347–52.
- Colecchia A, Montrone N, Scailoi E, Bacchi-Reggiani ML, Colli A, Casazza G, et al. Measurement of Spleen Stiffness to Evaluate Portal Hypertension and the Presence of Oesophageal Varices in Patients With HCV-Related Cirrhosis. Gastroenterology 2012;143(3):646–4.
- Augustin S, Millan M, Gonzalez A, Martell M, Gelabert A, Segarra A, et al. Detection of early portal hypertension with routine data and liver stiffness in patients with asymptomatic liver disease: A prospective study. J Hepatol 2014;60(3):561–9.
- Leomine M, Katsahian S, Ziol M, Nahon P, Ganne-Carrie N, Kazemi F, et al. Liver stiffness measurement as a predictive tool of clinically significant portal hypertension in patients with compensated hepatitis C or alcohol-related cirrhosis. Aliment Pharmacol Ther 2008;28(9):1102–10.

Submitted: March 3, 2022 Revised: May 10, 2022 Accepted: May 10, 2022

# **Address for Correspondence:**

Syed Zea Ul Islam Farrukh, A 309 Block 3 Gulshan-e-Iqbal, Karachi-Pakistan

**Cell:** +92 3452973753

Email: dr zea@hotmail.com